The clinical value of Xinhuosu in patients with coronary heart disease and acute heart failure
Objective To analyze the clinical value of lyophilized recombinant human brain natriuretic peptide(trade name:Xinhuosu)in patients with coronary heart disease and acute heart failure.Methods 60 patients with coronary heart disease and acute heart failure were divided into a control group and a study group according to the random numerical table,with 30 cases in each group.The control group was treated with isosorbide dinitrate,and the study group was treated with isosorbide dinitrate and Xinhuosu.The clinical therapeutic effect and the vital signs[diastolic blood pressure,systolic blood pressure,heart rate,N-terminal pro-brain natriuretic peptide(NT-proBNP)]before and after treatment were compared between the two groups.Results Compared with the control group(80.00%),the total effective rate of the study group(96.67%)was significantly higher,and the difference between groups was statistically significant(χ2=4.043,P<0.05).After treatment,the diastolic blood pressure,systolic blood pressure,heart rate and NT-proBNP levels in both groups were significantly lower than those before treatment;the study group had diastolic blood pressure of(83.11±2.13)mm Hg(1 mm Hg=0.133 kPa),systolic blood pressure of(108.37±4.62)mm Hg,heart rate of(82.16±1.74)beats/min,and NT-proBNP of(1251.39±46.23)pg/ml,which were significantly lower than(87.16±2.72)mm Hg,(123.28±4.19)mm Hg,(87.16±2.16)beats/min,and(1763.27±95.16)pg/ml in the control group;the difference between groups was statistically significant(P<0.05).Conclusion The application of Xinhuosu in the treatment of coronary heart disease combined with acute heart failure can effectively regulate the patient's heart function,promote the prognosis of patients,and improve the overall efficacy.It has high clinical application value,and is worth promoting.
Coronary heart diseaseAcute heart failureLyophilized recombinant human brain natriuretic peptideClinical value
万方数据
维普
